FDA Approves New Drug for Ulcerative Colitis

If you live with ulcerative colitis, you probably have a mental spreadsheet of every flare, every colonoscopy, and every medication that promised the world and delivered… mixed results. The good news? The U.S. Food and Drug Administration (FDA) has been busy in the last few years, approving a wave of new drugs that are changing what treatment can look like for people with moderate to severe ulcerative colitis (UC).

One of the newest kids on the block is risankizumab-rzaa (Skyrizi), approved in 2024 for adults with moderately to severely active ulcerative colitis. It joins other recent approvals like mirikizumab (Omvoh) and etrasimod (Velsipity), giving doctors more options and patients more hope. While the brand names may sound like fantasy RPG characters, these are highly targeted therapies with serious science behind them.

In this guide, we’ll walk through what ulcerative colitis is, what a “new drug approval” really means, how these newer treatments work, and what questions to ask your care team if you’re wondering whether a newly approved UC drug might be right for you.

Ulcerative Colitis 101: Why New Treatments Matter

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that affects the colon and rectum. In UC, the immune system overreacts and attacks the lining of the large intestine, causing inflammation, ulcers, bleeding, diarrhea, urgency, and abdominal pain. Symptoms can range from annoying to life-disruptingand for some people, downright disabling.

Traditional treatments have included:

• Aminosalicylates (such as mesalamine) for milder disease.
• Corticosteroids for short bursts when flares are bad.
• Immunomodulators (azathioprine, 6-MP) to dampen the immune system.
• Biologic drugs like anti-TNF agents (infliximab, adalimumab) and anti-integrin or anti-IL-12/23 therapies.

While these medications have helped many people, they don’t work for everyone, and some people lose response over time. That’s why new drug approvals are a big deal: every fresh option is another chance to get inflammation under control and reduce the risk of complications like hospitalization, surgery, and colorectal cancer.

The New Wave of Ulcerative Colitis Drugs

Instead of one single “miracle pill,” we’re seeing a cluster of new UC therapies approved over the last few years. Think of it as a treatment upgrade era rather than a one-time announcement.

Skyrizi (risankizumab): A New IL-23 Inhibitor for UC

Skyrizi, originally known for treating psoriasis and Crohn’s disease, was approved in 2024 for adults with moderately to severely active ulcerative colitis. It targets a specific immune pathway called interleukin-23 (IL-23), a key driver of inflammation in IBD.

In clinical trials, a meaningful number of patients on Skyrizi achieved:

• Clinical remission (minimal or no symptoms).
• Endoscopic improvement (the colon actually looked better on scope).
• Sustained benefit over time with continued treatment.

One standout point from real-world reporting and trial data: more patients remained in remission at 52 weeks compared with placebo, which is exactly what people with UC wantrelief that sticks, not a two-week honeymoon.

Omvoh (mirikizumab): First-in-Class IL-23 Antagonist

Another major newcomer is Omvoh (mirikizumab), originally approved in 2023 for adults with moderately to severely active ulcerative colitis. It also targets IL-23, but with its own dosing schedule and data set. Omvoh has since gained additional approvals for Crohn’s disease and even a simplified single-injection maintenance regimen, making ongoing treatment less of a time-suck for patients.

The big idea: by selectively blocking IL-23, Omvoh helps calm down the immune storm in the gut without suppressing the entire immune system as broadly as older therapies can.

Velsipity (etrasimod): A Once-Daily Oral Option

Not a fan of injections? Velsipity (etrasimod), approved in 2023, is taken by mouth once a day. It’s a selective sphingosine-1-phosphate (S1P) receptor modulator, which is a fancy way of saying it affects how certain white blood cells move in and out of the lymph nodes and into the gut.

In phase 3 trials, people taking Velsipity were more likely than those on placebo to achieve clinical remission and mucosal healing. For many patients, the appeal is pretty straightforward: a targeted immune therapy that doesn’t require an IV or injection.

Other Recent Approvals and Biosimilars

Beyond Skyrizi, Omvoh, and Velsipity, the FDA has also:

• Approved Tremfya (guselkumab) for UC, adding yet another IL-23 inhibitor to the toolbox.
• Cleared several adalimumab and ustekinumab biosimilars that can be used in UC, helping expand access and potentially reduce costs.

The short version: there’s no single “new drug” – there is a rapidly growing family of newly approved options for ulcerative colitis, each with its own pros and cons.

How These New Drugs Work (Without a PhD in Immunology)

All of these newer therapies share one major goal: cool down the immune system in the gut just enough to stop it from attacking your colon, but not so much that you’re left completely defenseless.

Here’s the 30-second version:

• IL-23 inhibitors (Skyrizi, Omvoh, Tremfya) block a specific molecule that fuels inflammation in the gut. Think of it as taking away the megaphone from an overexcited immune cell.
• S1P modulators (Velsipity) reduce the number of overactive immune cells that can travel from the lymph nodes to the intestine.
• Biosimilars closely mimic older biologics (like adalimumab or ustekinumab) but may broaden access and choice.

The end result is often less bleeding, fewer bathroom trips, less urgency, less painand in many cases, visible healing inside the colon.

Who Might Be a Candidate for a Newly Approved UC Drug?

You might hear about a new FDA approval and immediately think, “Great, sign me up!” But in practice, doctors match therapies to people based on several factors:

• Severity of your UC (mild, moderate, severe).
• How much of your colon is affected (proctitis vs. extensive colitis).
• Response to past treatments (did you fail or lose response to 5-ASA, steroids, or older biologics?).
• Other health issues such as heart disease, infections, liver disease, or a history of blood clots.
• Your lifestyle and preferences (OK with IV infusions? Prefer a monthly injection? Really want a pill?).

Newly approved drugs are often used for moderate to severe UC in people who:

• Haven’t responded well to older medications, or
• Can’t tolerate side effects, or
• Want a treatment that fits better with their daily life.

Only a gastroenterologist who knows your medical history can say whether a specific new drug is a good match for you, so think of this article as background informationnot a DIY prescribing guide.

What FDA Approval Actually Means

When the FDA approves a new drug or a new indication for an existing drug, it means:

• The drug has gone through multiple phases of clinical trials with hundreds or sometimes thousands of patients.
• It has shown a meaningful benefit over placebo or an existing therapyoften things like higher remission rates or better mucosal healing.
• Known risks and side effects are judged acceptable compared with the benefits, especially for a serious chronic disease like UC.
• There will be ongoing post-marketing safety surveillance to catch any long-term or rare side effects.

FDA approval doesn’t mean a drug is perfect or risk-free. It means the agency believes the benefits outweigh the risks when used appropriately in the right patients.

Side Effects and Safety: The Not-So-Fun but Very Important Part

Because these medications modulate the immune system, some of the most important safety issues include:

• Infection risk: Higher risk of certain infections, especially if you’re also on steroids or other immunosuppressants.
• Lab changes: Some drugs require regular blood tests to watch liver function, blood counts, or cholesterol.
• Specific warnings: Certain drugs may carry warnings about heart disease, blood clots, or malignancy risk, depending on their class.

Before starting a newly approved UC medication, your doctor may:

• Check for tuberculosis and hepatitis.
• Review your vaccine status.
• Go over your entire medication list to avoid dangerous interactions.

This is why those pre-treatment visits feel so thoroughand why you should always mention even the “small” stuff, like herbal supplements or over-the-counter meds.

Insurance, Cost, and Access

Here’s the not-so-secret secret: many newly approved drugs are expensive. However, you are not automatically doomed to pay list price.

In practice, people often access these drugs through a combination of:

• Insurance coverage (often with prior authorization).
• Manufacturer copay cards for those with commercial insurance.
• Patient assistance programs for people who are under-insured or uninsured.

If your doctor suggests a newly approved drug, ask to speak with the clinic’s financial counselor, social worker, or specialty pharmacy team. They live in the land of forms and phone calls so you don’t have to.

How to Talk to Your Doctor About a Newly Approved UC Drug

Not sure how to bring this up without sounding like you’re quoting an ad? Try questions like:

• “I heard the FDA recently approved new medications for ulcerative colitis. Do any of those make sense for my situation?”
• “I’m still having symptoms on my current treatment. Could we look at options like Skyrizi, Omvoh, or Velsipity?”
• “What are the pros and cons of switching from my current drug to one of the newer therapies?”
• “How would monitoring and lab tests change if I started a newer medication?”

A good IBD provider won’t be offended that you’ve done your homework. If anything, it makes the visit more productive.

500-Word Experience Section: What Starting a New UC Drug Really Feels Like

Clinical trial graphs are great, but they don’t exactly capture what it’s like to sit there on infusion day, wondering if this is the medication that finally changes your life. While every person’s story is unique, some themes show up again and again when patients and clinicians talk about starting a newly approved drug for ulcerative colitis.

First, there’s usually a mix of hope and fatigue. Many people land on newer drugs after years of trying other therapies5-ASA, steroids, maybe an older biologic or two. By the time a doctor suggests something like Skyrizi, Omvoh, or Velsipity, patients often say, “I’m excited, but I’m also tired of being excited and then disappointed.” Doctors recognize this emotional whiplash, which is why they often pair a new treatment plan with clear expectations and short-term milestones: fewer bathroom trips, more energy, maybe the ability to make plans without mapping every restroom in a 10-mile radius.

The logistics can be an adjustment too. Some people actually prefer an IV or injection“Just give it to me and I’m done for the month.” Others feel more in control with a daily pill, even if it means another line in the pillbox. Newly approved drugs often come with support programs that walk patients through their first dose, provide nurse hotlines, and help troubleshoot things like storage and administration. That hands-on support can make a big difference in the first few months when everything still feels new and slightly terrifying.

Then there’s the waiting game. These medications don’t flip a switch overnight. Some people notice incremental improvements in just a few weeks; for others, it may take several months before the full benefit shows up. Patients often describe “sneaky progress”realizing one day that they got through a work meeting, a school play, or a dinner out without even thinking about where the nearest bathroom was. Those quiet wins can be as meaningful as any lab result.

On the clinician side, gastroenterologists are cautiously optimistic about the expanding menu of options. Many describe tailoring therapy more precisely than ever beforematching drug mechanism and dosing to each patient’s disease characteristics, history, and preferences. They watch closely for side effects and loss of response, but they also see patients achieving deeper remission, both symptom-wise and on endoscopy, than what was often possible 10 or 15 years ago.

Perhaps the emotional heart of starting a newly approved drug is the possibility of reclaiming normal life. For some, that might mean traveling without fear. For others, it’s having the energy to chase kids, finish school, or simply get through the day without planning every move around their colon. Not every new drug is a miracle, and no therapy works for everyonebut when a newly approved UC treatment does click, the impact can feel nothing short of life-changing.

Bottom Line: More Options, More Hope

The recent FDA approvals for ulcerative colitisSkyrizi, Omvoh, Velsipity, Tremfya, and several biosimilarssignal a major shift in how this disease can be managed. Instead of a one-size-fits-all approach, patients and providers can increasingly pick from a range of targeted options with different mechanisms, dosing schedules, and safety profiles.

If you’re still struggling with symptoms or side effects on your current regimen, it’s worth asking your gastroenterologist whether one of the newly approved drugs for ulcerative colitis might be appropriate for you. There’s no guarantee, but there are more paths forward than everand that alone is a big step in the right direction.